The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: A case report

BMC Ophthalmology

Volumn 17, Issue 1, 2017, Pages

  Hong, Eun Hee ^a   Ahn, Seong Joon ^a   Lim, Han Woong ^a   Lee, Byung Ro ^a  

^a Hanyang University   (South Korea)

Author keywords

Acetazolamide; Case report; Cystoid macular edema; Hydroxychloroquine retinopathy

Indexed keywords

ACETAZOLAMIDE; ANTIRHEUMATIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; HYDROXYCHLOROQUINE;

CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACULAR EDEMA; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RETINA; RETINAL DISEASES; VISUAL ACUITY;

ACETAZOLAMIDE; ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACULAR EDEMA; MIDDLE AGED; RETINA; RETINAL DISEASES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 85023188912     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/s12886-017-0517-0     Document Type: Article

References (27)

1. Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol. 2014;98:200-6.
2. Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141:850-8.
3. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106:1190-5.
4. Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol. 1989;107:1445-52.
5. Fishman GA, Gilbert LD, Anderson RJ, Marmor MF, Weleber RG, Viana MA. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology. 1994;101:687-93.
6. Moldow B, Sander B, Larsen M, Engler C, Li B, Rosenberg T, Lund-Andersen H. The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol. 1998;236:881-9.
7. Wolfensberger TJ. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol. 1999;97:387-97.
8. Marmor MF. Efficient and effective screening for hydroxychloroquine toxicity. Am J Ophthalmol. 2013;155:413-4.
9. Anderson C, Blaha GR, Marx JL. Humphrey visual field findings in hydroxychloroquine toxicity. Eye (Lond). 2011;25:1535-45.
10. Brown DM, s Benz M, Wong TP, Major JC. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). Clin Ophthalmol. 2010;4:1151-8.
11. Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology. 2015;122:110-6.
12. Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, Yoo B, Koo BS, Kim JT, Marmor MF, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology. 2015;122:1252-6.
13. Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. General pathophysiology of macular edema. Eur J Ophthalmol. 2011;21(Suppl 6):S10-9.
14. Marks J. Chloroquine retinopathy: is there a safe daily dose? Ann Rheum Dis. 1982;41:52-8.
15. Cunha-Vaz JG, Travassos A. Breakdown of the blood-retinal barriers and cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):485-92.
16. Fishman GA, Cunha-Vaz J, Salzano T. Vitreous fluorophotometry in patients with retinitis pigmentosa. Arch Ophthalmol. 1981;99:1202-7.
17. Kuchle M, Nguyen NX, Martus P, Freissler K, Schalnus R. Aqueous flare in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 1998;236:426-33.
18. Mallick KS, Zeimer RC, Fishman GA, Blair NP, Anderson RJ. Transport of fluorescein in the ocular posterior segment in retinitis pigmentosa. Arch Ophthalmol. 1984;102:691-6.
19. Vinores SA, Kuchle M, Derevjanik NL, Henderer JD, Mahlow J, Green WR, Campochiaro PA. Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. Histol Histopathol. 1995;10:913-23.
20. Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T. Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013;120:e5-12.
21. Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013;120:100-5.
22. Bhavsar KV, Mukkamala LK, Freund KB. Multimodal imaging in a severe case of hydroxychloroquine toxicity. Ophthalmic Surg Lasers Imaging Retina. 2015;46:377-9.
23. Parikh VS, Modi YS, Au A, Ehlers JP, Srivastava SK, Schachat AP, Singh RP. Nonleaking cystoid macular edema as a presentation of hydroxychloroquine retinal toxicity. Ophthalmology. 2016;123:664-6.
24. Takahashi J, Mori F, Hikichi T, Yoshida A. Effect of acetazolamide on outward permeability of blood-retina barrier using differential vitreous flyorophotometry. Curr Eye Res. 2001;23:166-70.
25. Moldow B, Sander B, Larsen M, Lund-Andersen H. Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB. Invest Ophthalmol Vis Sci. 1999;40:1770-5.
26. Miller SS, Steinberg RH. Active transport of ions across frog retinal pigment epithelium. Exp Eye Res. 1977;25:235-48.
27. Marmor MF, Maack T. Enhancement of retinal adhesion and subretinal fluid resorption by acetazolamide. Invest Ophthalmol Vis Sci. 1982;23:121-4.